Response to: ‘Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’’ by Perriconeet al
Open Access
- 28 January 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 82 (4), e82
- https://doi.org/10.1136/annrheumdis-2021-219898
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Anti-inflammatory therapy for COVID-19 infection: the case for colchicineAnnals Of The Rheumatic Diseases, 2020
- Therapy for Early COVID-19JAMA, 2020
- Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19Journal of Clinical Medicine, 2020
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis & Rheumatology, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- 2016 updated EULAR evidence-based recommendations for the management of goutAnnals Of The Rheumatic Diseases, 2016
- Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.JCI Insight, 1995